Code of Maine Rules
02 - DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
380 - STATE BOARD OF NURSING
Chapter 1 - COLLABORATIVE DRUG THERAPY MANAGEMENT
Section 380-1-1 - Definitions

Current through 2024-13, March 27, 2024

1. Board. For purposes of this chapter, "Board" means the Maine Board of Pharmacy.

2. Collaborative drug therapy management. "Collaborative drug therapy management" is defined in 32 MRS §13702-A(2-A). The statutory requirements for collaborative drug therapy management are set forth in 32 MRS §§13841 - 13847.

3. Collaborative practice agreement. "Collaborative practice agreement" is defined in 32 MRS §13702-A(2-B).

4. Practitioner. "Practitioner" is defined in 32 MRS §13702-A(29).

5. Qualifying condition. "Qualifying condition" means a condition or disease with generally accepted standards of care, which may include, but is not limited to, the following examples:

A. Anticoagulation

B. Asthma

C. Diabetes

D. Dyslipidemia

E. Hyperlipidemia

F. Hypertension

G. Infectious Disease

H. Cancer

I. Thyroid Disorder

6. Treatment protocol. "Treatment protocol," as referenced in 32 MRS §13845, means the written document by which the nurse practitioner describes the activities of drug therapy management in which the pharmacist is authorized to engage under a collaborative practice agreement and specifies the procedures and parameters of that practice authority.

7. Unrestricted pharmacist license. "Unrestricted pharmacist license" means a pharmacist license, the holder of which is not subject to any conditions of licensure affecting the scope of practice.

Disclaimer: These regulations may not be the most recent version. Maine may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.